Sai Life Sciences Limited has issued a revised intimation regarding the allotment of equity shares under its Employee Stock Option Plans, correcting an earlier omission. The company initially reported the allotment of 1,29,007 shares but has now revised this to 1,39,007 shares after inadvertently omitting 10,000 ESOP shares from the previous intimation dated February 23, 2026.

Revised Share Allotment Details

The Board of Directors approved the allotment of fully paid-up equity shares of Re.1 each on February 22, 2026, under two distinct employee stock option schemes:

The shares have been issued in dematerialized form with distinctive numbers ranging from 211629128 to 211768134. All shares carry the ISIN number INE570L01029 and are identical to existing equity shares in all respects.

Financial Impact

The revised exercise of stock options generated increased proceeds for the company:

Regulatory Compliance and Filing

The company has filed the required statements with BSE and NSE on January 08, 2025, receiving filing numbers for both exchanges under each scheme. The revised intimation was submitted on February 26, 2026, signed by Company Secretary & Compliance Officer Runa Karan.

Scheme Characteristics

Both ESOP schemes are designed to attract, retain, and reward employees while contributing to the company's growth. The schemes feature a maximum vesting period of 5 years with multiple vesting options and exercise periods extending until the employee remains in company service. The pricing is determined by the Nomination and Remuneration Committee in compliance with applicable accounting standards and SEBI regulations.

The allotment has been conducted in full compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The shares are not subject to any lock-in restrictions and no additional listing fees are payable for this allotment.

Sai Life Sciences Limited has submitted its monitoring agency report for Q3FY26 to stock exchanges, detailing the utilization of proceeds from its Initial Public Offer (IPO) conducted in December 2024. The report, prepared by CRISIL Ratings Limited as the appointed monitoring agency, demonstrates substantial progress in deploying the raised capital across designated objectives.

Regulatory Compliance and Monitoring Framework

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the monitoring agency report for the quarter and nine months ended December 31, 2025. CRISIL Ratings Limited, appointed as the monitoring agency under Regulation 41(2) of SEBI ICDR Regulations, oversees the utilization of IPO proceeds through quarterly assessments.

IPO Proceeds Utilization Status

The company's IPO raised gross proceeds of Rs. 9,500.00 million through fresh issue, with net proceeds of Rs. 9,098.84 million after deducting issue expenses of Rs. 401.16 million. As of December 31, 2025, the company has utilized Rs. 9,444.72 million of the total proceeds, leaving Rs. 55.28 million unutilized and parked in fixed deposits and public offer accounts.

Object-wise Deployment of Funds

The monitoring report reveals complete utilization of funds allocated for debt repayment and general corporate purposes. During Q3FY26, the company transferred Rs. 963.03 million from the monitoring account to cash credit accounts for vendor payments under general corporate purposes, specifically for equipment and machinery purchases.

Investment of Unutilized Proceeds

The remaining Rs. 55.28 million is strategically deployed across fixed deposits and bank accounts to ensure capital preservation while maintaining liquidity. The company has invested Rs. 36.97 million in IndusInd Bank fixed deposits earning 5.45% returns, with the balance maintained in public offer and monitoring accounts.

The monitoring agency confirmed no deviations from disclosed objects, with all utilization proceeding as per the offer document. The company maintains full regulatory compliance with no material deviations requiring shareholder approval, demonstrating effective capital deployment aligned with stated IPO objectives.